35.14

3.23% 1.10

Pharvaris Nv (PHVS)

Overview News Price History Discussions Forecast

Pharvaris Nv stock is traded at $35.14, with a volume of 862.88K. It is up +3.23% in the last 24 hours and up +2.09% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Previous Close:

$34.04

Open:

$34

24h Volume:

862.88K

Relative Volume:

1.92

Market Cap:

$2.46B

Revenue:

Net Income/Loss:

$-195.21M

P/E Ratio:

-11.06

EPS:

-3.1763

Net Cash Flow:

$-176.19M

1W Performance:

+0.66%

1M Performance:

+2.09%

6M Performance:

+32.85%

1Y Performance:

+52.85%

1-Day Range:

$33.54

$36.18

1-Week Range:

$33.00

$36.93

52-Week Range:

$20.65

$36.93

Pharvaris Nv Stock (PHVS) Company Profile

Name

Pharvaris Nv

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

Address

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHVS Pharvaris Nv	35.14	2.55B	0	-195.21M	-176.19M	-3.1763
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-09-26	Initiated	RBC Capital Mkts	Outperform
Oct-15-25	Initiated	H.C. Wainwright	Buy
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-11-25	Initiated	Guggenheim	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris Nv Stock (PHVS) Latest News

Aug 14, 2026

General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership - Stock Titan

Aug 14, 2026

H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress By Investing.com - Investing.com Nigeria

Aug 14, 2026

Aug 13, 2026

Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions - Kalkine Media

Aug 13, 2026

PHVS Maintains Outperform Rating -- Price Target Raised to $52.0 - GuruFocus

Aug 13, 2026

Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says - marketscreener.com

Aug 13, 2026

PHVS Maintains Rating by Citizens -- Price Target Raised to $75.00 - GuruFocus

Aug 13, 2026

RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating - marketscreener.com

Aug 13, 2026

Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com Nigeria

Aug 13, 2026

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighWhat's Next? - MarketBeat

Aug 13, 2026

Aug 12, 2026

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat

Aug 12, 2026

Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate - scanx.trade

Aug 12, 2026

Pharvaris N.V. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

(PHVS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Aug 12, 2026

Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones - TipRanks

Aug 12, 2026

Pharvaris' Q2 Loss Per Share Narrows - marketscreener.com

Aug 12, 2026

Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share - marketscreener.com

Aug 12, 2026

Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position - Quiver Quantitative

Aug 12, 2026

Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date - Stock Titan

Aug 12, 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update - Enidnews.com

Aug 12, 2026